A detailed history of Beacon Pointe Advisors, LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Beacon Pointe Advisors, LLC holds 161,600 shares of NUVB stock, worth $785,376. This represents 0.01% of its overall portfolio holdings.

Number of Shares
161,600
Previous 211,950 23.76%
Holding current value
$785,376
Previous $413,000 44.55%
% of portfolio
0.01%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 13, 2025

SELL
$1.94 - $3.9 $97,679 - $196,365
-50,350 Reduced 23.76%
161,600 $597,000
Q2 2025

Aug 13, 2025

BUY
$1.66 - $2.53 $140,934 - $214,796
84,900 Added 66.82%
211,950 $413,000
Q1 2025

May 13, 2025

BUY
$1.76 - $3.25 $129,360 - $238,875
73,500 Added 137.25%
127,050 $223,000
Q4 2024

Feb 14, 2025

BUY
$2.01 - $3.01 $107,635 - $161,185
53,550 New
53,550 $142,000
Q4 2023

Feb 08, 2024

BUY
$0.96 - $1.53 $20,832 - $33,201
21,700 New
21,700 $32,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $1.06B
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Beacon Pointe Advisors, LLC Portfolio

Follow Beacon Pointe Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Beacon Pointe Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Beacon Pointe Advisors, LLC with notifications on news.